Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

CAMBRIDGE, Mass. , April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hematological disorders, today announced that Josh Lehrer, M. D. , M.